MedTrace Logo

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

NCT00004903 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2014-01-06

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and peripheral stem cell transplantation in treating patients who have multiple myeloma.

Conditions

  • Multiple Myeloma and Plasma Cell Neoplasm

Interventions

PROCEDURE

peripheral blood stem cell transplantation

BIOLOGICAL

filgrastim

BIOLOGICAL

recombinant interferon alfa

DRUG

cisplatin

DRUG

cyclophosphamide

DRUG

cytarabine

DRUG

etoposide

DRUG

melphalan

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Robert H. Lurie Cancer Center

    lead OTHER

Principal Investigators

  • Jane N. Winter, MD · Robert H. Lurie Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004903 on ClinicalTrials.gov